Translational medicine as a permanent glue and force of clinical medicine and public health: perspectives (1) from 2012 Sino‐American symposium on clinical and translational medicine

Zhou, Jiaxin; Wu, Duojiao; Liu, Xinqing; Yuan, Shuoqi; Yang, Xiaobin; Wang, Xiangdong

doi:10.1186/2001-1326-1-21

Cited by 5 publications

(3 citation statements)

References 17 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The term "translational medicine" has been used in article title dating back to 1996 [9]. Multiple papers have specifically discussed the question of what translational medicine or translational research actually is [10][11][12]. While it seems that the importance of translational medicine is well-accepted and vigorously promoted by scientists, clinicians, physician scientists, funding agencies, policy makers, and medical industries, the true meaning of translational medicine is still debatable.…”

Section: Discussionmentioning

confidence: 99%

Perspectives of Translational Medicine

Lingqun¹,

John²,

Tu³

et al. 2015

Transl Perioper & Pain Med

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Perspectives of Translational Medicine

Lingqun¹,

John²,

Tu³

et al. 2015

Transl Perioper & Pain Med

View full text Add to dashboard Cite

“…The functions of these CROs are to assist disease diagnosis by various biomarkers, to visualize the progression of the disease with advanced image analysis technology, to formulate the deliverables by maximizing the intended therapy, to target the specific/vulnerable subpopulation by meta-analysis and epidemiology, and to treat patients with a personalized care system. CROs, swiftly evolving in accordance with market needs, have become the essential vehicle to deliver translational medicine [12] . The main recipients of the most beneficial results from this new paradigm are the patients.…”

Section: Collaboration Between Sponsors and Crosmentioning

confidence: 99%

Roles of contract research organizations in translational medicine

Shih¹

2015

Journal of Orthopaedic Translation

View full text Add to dashboard Cite

SummaryTransitional medicine/science is shifting the medical research paradigm from compound-based to evidence-based drug/device discovery. It is increasing interdisciplinary collaborations, enhancing usage of advanced technologies, and facilitating therapeutics reaching patients faster. The fundamental theme of evidence-based discovery is to apply what is revealed in preclinical experimentation and to bring the resulting safety and efficacy to clinics. In the medical fields, a contract research organization (CRO) works like a hired agent who has corresponding knowledge and experience to conduct and complete tasks for a sponsor. The relationship is business, and the contract is for deliverables. The increasingly high volume of sponsored outsourcing work has made this for-profit business boom in the past decade. Location boundaries are being blurred under globalization in the sciences and cross-border regulatory reviews. Getting from bench to bedside is a winding road with many obstacles and high hurdles. Efficient teamwork becomes essential to materialize ideas and bring them to the market. The professionals within team communities include drug/device makers and CROs. It has become increasingly obvious that CROs play pivotal roles in the chain of discovery/design, developing product to market through in vitro, in vivo, and ex vivo testing during preclinical experimentations and clinical trials. Project management teams are responsible for nurturing the materialization in a collaborative manner and enhancing the productivity of the pipelines. CROs have many functional aspects and specialties, and no one organization is fully capable of serving, i.e., integrated services, with expertise in each step of the chain to the needs of a variety of sponsors. Instead of competition among the CROs themselves, the continuously expanding market demands can be shared by Expertise-Based Integrated Services among allied CROs, in contrast to the few large CROs. Empirically, the data generated from the chosen CROs should meet the regulatory requirements for approval. A quality assurance unit from the sponsor should be vigilant in performing audits and inspections of the candidate CROs prior to contracting. Subsequently, close monitoring and well-organized project management guard the path to the successful filing of the applications. A strategic alliance of translational medicine with CROs ensures proven therapeutics for disease treatment and prevention to be connected with patient populations in a timely and cost-effective manner. The unbiased data generated through CROs' services can be used for a patient-driven approach in drug discovery and device control design. Thereafter, findings from the merged efforts can promote and complete the feedback loop for refining existing medicines and exploring new medicines. A matchmaking business may emerge and evolve from the procurement department of the inventor in translational medicine and the business development sector of the CROs to generate a new landscape in translational medicine.

show abstract

“…The pursuit of translational research has historically been dependent on collaboration and communication between disciplines. The “bench to bedside” concept, harnessing knowledge from basic sciences to produce “new approaches for prevention, diagnosis and treatment of diseases” in clinical settings [ 1 ] implies a connection between basic scientists and clinicians [ 2 ]. But the strength of this connection is sometimes tenuous and the US Institute of Medicine has identified two “translational blocks” in the undertaking of clinical research: (T1) “the transfer of new understandings of disease mechanisms gained in the laboratory into the development of new methods for diagnosis, therapy, and prevention and their first testing in humans” and (T2) “the translation of results from clinical studies into everyday clinical practice and health decision making” [ 1 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Overcoming the translational roadblocks: a cancer care and research model

Braun

Daudt

Watson

2014

Clinical & Translational Med

View full text Add to dashboard Cite

There are many challenges to the process of translating the knowledge gained in the laboratory into new clinical approaches that can meet the needs of patients, clinicians and the wider community. We describe here an initiative that has borrowed concepts and principles from participatory research to produce a new process embedded in a cancer center aiming to facilitate translational research and overcome the three translational roadblocks. The centre‐wide project named Personal Response Determinants in Cancer Therapy (PREDICT) operates with the support of the centre's leadership, staff, volunteers and patients to contribute to current and future cancer research successes. We describe the different phases of the project, the current structure and lessons learned during its evolution, highlighting how PREDICT contributes to translational research and its linkage to participatory research concepts. Despite the contextualized nature of the PREDICT initiative, we believe that the framework developed for the project has the potential to help other clinical centers to overcome the translational research roadblocks.

show abstract

Translational medicine as a permanent glue and force of clinical medicine and public health: perspectives (1) from 2012 Sino‐American symposium on clinical and translational medicine

Cited by 5 publications

References 17 publications

Perspectives of Translational Medicine

Perspectives of Translational Medicine

Roles of contract research organizations in translational medicine

Overcoming the translational roadblocks: a cancer care and research model

Contact Info

Product

Resources

About